Zim Laboratories Announces New Granted US Patent
Kamleshwar, Maharashtra (IN), May 09, 2020 – ZIM Laboratories Limited, a leading pharmaceutical technology company has announced that the United States Patent and Trademark Office has issued US Patent 10,660,862 B2 dated May 26, 2020. The patent is titled, “PHARMACEUTICAL MICROEMULSION – IMMOBILIZED IN A THIN POLYMER MATRIX AND METHODS OF MAKING THEM”.
The invention pertains to stable microemulsions immobilized in a thin polymer matrix compositions and a process of making the same. In particular, the invention pertains to stable pharmaceutical microemulsion by immobilization in the polymer matrix. Microemulsions are well-known vehicles for drug delivery that can be used to enhance penetration and absorption of active pharmaceutical ingredients from the site of administration. Controlling the release rate of drugs, enhancing stability and taste masking are some more uses of microemulsions. Thin films are recently becoming very popular dosage form among special needs patient populations because of the patient convenience and therapeutic regimen compliance-related advantages. Thin-films can be given by topical, oral, buccal, sublingual, nasal, vaginal, and rectal routes of administration. Immobilizing microemulsions into a thin-film matrix will combine the advantages of both the delivery systems and forms a unique drug delivery system.
It is a very convenient dosage form for the delivery of pharmaceutical drugs, especially for children, old aged patients, and people with motor neuron conditions who cannot administer solid dosages themselves.
“This is our first granted US patent”, says Dr. Anwar Daud, MD at ZIM Laboratories., “and it shows how we have grown into one of the leading companies that are working on Thin Film Technology”. This patent accentuates the Research & Development efforts of ZIM Laboratories and how insightful and competitive their research teams are. Several molecules and many large molecules can’t be delivered by non-invasive routes because of the poor bioavailability. This technology will enable the delivery of such molecules by non-invasive routes. With the addition of this technology company’s thin-film manufacturing capabilities have been strengthened.
According to a report by Transparency Market Research (TMR), the global market for Oral Thin Films was valued at US$ 2,100.0 Million in 2017 and is expected to expand at a CAGR of 13.0% during the forecast period from 2018 to 2026.
About ZIM Laboratories
ZIM Laboratories Limited is an innovative drug delivery solution provider focusing on improving patient convenience and adherence to drug intake. It offers a range of technology-based drug delivery solutions and non-infringing proprietary manufacturing processes for the production and supply of innovative and differentiated generic pharmaceutical products to global customers.
ZIM Laboratories also provides its customers with a comprehensive range of value-added solid dosage differentiated generic products in semi-finished and finished categories/formulations including include granules, pellets, taste-masked powders, suspensions, tablets, capsules and it’s recently developed Oral Thin Films (OTF).